Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.

Wang JY, Kang JW, Peng TR, Chen HY, Chen SM, Lee MC

Clinical obesity21 Jul 2025Cited by 1 (Europe PMC)

PMID40685889DOI10.1111/cob.70036PepBankPUB-40685889

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in adults with obesity, tirzepatide reduced body weight more than placebo, with a pooled mean difference of -11.62 kg.
In plain wordsIn adults with obesity, trials combined showed tirzepatide cut body weight more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody weight, pooled mean difference versus placebo
Study
n = 6,257
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Pooled mean difference
−11.62 kg
tirzepatide vs placebo
Source sentences
Summary
Tirzepatide significantly reduced body weight compared to placebo, with a total pooled mean difference of -11.62 kg (95% confidence interval: -14.24 to -9.01, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588901
02HumanSystematic reviewSafety outcome
In the meta-analysis of tirzepatide versus placebo RCTs, tirzepatide did not increase the risk of serious adverse events.
In plain wordsIn these trials, tirzepatide did not raise the risk of serious side effects compared with placebo.
Peptide
Tirzepatide
Outcome
No significant changeSerious adverse events
Study
n = 6,257
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
without increasing the risk of serious adverse events
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588909
03HumanSystematic reviewSafety outcome
In the meta-analysis of tirzepatide versus placebo RCTs, tirzepatide did not affect mortality rates.
In plain wordsIn these trials, tirzepatide did not change the number of deaths compared with placebo.
Peptide
Tirzepatide
Outcome
No significant changeMortality
Study
n = 6,257
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
Dose not stated
Source sentences
Summary
or impacting mortality rates.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588910
04HumanSystematic reviewEfficacy outcome
In the 15 mg group of the pooled trials in adults with obesity, 88.1% of participants achieved weight reductions exceeding 5%.
In plain wordsIn adults with obesity on the highest tirzepatide dose, most people lost more than 5% of body weight.
Peptide
Tirzepatide
Outcome
DecreaseWeight reduction above 5% with 15 mg
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Participants with weight reduction above 5%
88.1%
15 mg
Source sentences
Summary
In the highest dosage group of 15 mg, 88.1%, 63.3%, and 51.8% of participants achieved weight reductions exceeding 5%, 10%, and 15% respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588902
05HumanSystematic reviewEfficacy outcome
In the 15 mg group of the pooled trials in adults with obesity, 63.3% of participants achieved weight reductions exceeding 10%.
In plain wordsIn adults with obesity on the highest tirzepatide dose, about six in ten people lost more than 10% of body weight.
Peptide
Tirzepatide
Outcome
DecreaseWeight reduction above 10% with 15 mg
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Participants with weight reduction above 10%
63.3%
15 mg
Source sentences
Summary
In the highest dosage group of 15 mg, 88.1%, 63.3%, and 51.8% of participants achieved weight reductions exceeding 5%, 10%, and 15% respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588903
06HumanSystematic reviewEfficacy outcome
In the 15 mg group of the pooled trials in adults with obesity, 51.8% of participants achieved weight reductions exceeding 15%.
In plain wordsIn adults with obesity on the highest tirzepatide dose, about half of people lost more than 15% of body weight.
Peptide
Tirzepatide
Outcome
DecreaseWeight reduction above 15% with 15 mg
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Participants with weight reduction above 15%
51.8%
15 mg
Source sentences
Summary
In the highest dosage group of 15 mg, 88.1%, 63.3%, and 51.8% of participants achieved weight reductions exceeding 5%, 10%, and 15% respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588904
07HumanSystematic reviewEfficacy outcome
In the meta-analysis of tirzepatide versus placebo RCTs, haemoglobin A1C improved significantly.
In plain wordsIn adults in these trials, tirzepatide improved long-term blood sugar (HbA1c) more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseHaemoglobin A1C
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Significant improvements were also noted in cardiometabolic risk factors, including haemoglobin A1C, waist circumference, body mass index, and lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588905
08HumanSystematic reviewEfficacy outcome
In the meta-analysis of tirzepatide versus placebo RCTs, waist circumference improved significantly.
In plain wordsIn adults in these trials, tirzepatide reduced waist size more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Significant improvements were also noted in cardiometabolic risk factors, including haemoglobin A1C, waist circumference, body mass index, and lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588906
09HumanSystematic reviewEfficacy outcome
In the meta-analysis of tirzepatide versus placebo RCTs, body mass index improved significantly.
In plain wordsIn adults in these trials, tirzepatide lowered body mass index more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Significant improvements were also noted in cardiometabolic risk factors, including haemoglobin A1C, waist circumference, body mass index, and lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588907
10HumanSystematic reviewEfficacy outcome
In the meta-analysis of tirzepatide versus placebo RCTs, lipid profiles improved significantly.
In plain wordsIn adults in these trials, tirzepatide improved blood fat levels more than placebo.
Peptide
Tirzepatide
Outcome
MixedLipid profiles
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Significant improvements were also noted in cardiometabolic risk factors, including haemoglobin A1C, waist circumference, body mass index, and lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis following PRISMA guidelines, including randomised controlled trials (RCTs) comparing the efficacy and safety of Tirzepatide with placebo in adults with obesity, with or without type 2 diabetes.
Summary · context
Ten RCTs were included, comprising 6257 participants.
Report a problemFND-4068588908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.